Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $38.1 million.

  • PAVmed's Liabilities and Shareholders Equity changed N/A to $38.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.4 million, marking a year-over-year change of. This contributed to the annual value of $30.7 million for FY2024, which is 742.47% down from last year.
  • As of Q3 2025, PAVmed's Liabilities and Shareholders Equity stood at $38.1 million.
  • In the past 5 years, PAVmed's Liabilities and Shareholders Equity registered a high of $84.3 million during Q1 2022, and its lowest value of $25.0 million during Q3 2024.
  • Moreover, its 4-year median value for Liabilities and Shareholders Equity was $43.9 million (2025), whereas its average is $50.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 4293.72% in 2024, then surged by 4179.15% in 2025.
  • Quarter analysis of 4 years shows PAVmed's Liabilities and Shareholders Equity stood at $54.0 million in 2022, then plummeted by 38.65% to $33.1 million in 2023, then fell by 7.42% to $30.7 million in 2024, then increased by 24.17% to $38.1 million in 2025.
  • Its last three reported values are $38.1 million in Q3 2025, $43.9 million for Q2 2025, and $52.8 million during Q1 2025.